Approximately 90% of EGFR mutations in non‐small cell lung cancer (NSCLC) are “classic mutations” (19del, L858R, etc.)that are sensitive to treatment with EGFR tyrosine kinase inhibitors (TKIs).3, 4. The gene discussed is EGFR; the disease is lung cancer.